16:59 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

APLN17 analog identified for abdominal aortic aneurysm

DISEASE CATEGORY: Cardiovascular INDICATION: Aneurysm An analog of APLN17 could help treat abdominal aortic aneurysm (AAA). Levels of APLN, which is processed into APLN17 and other APLN peptides, were higher in diseased aorta from AAA...
20:30 , Oct 12, 2018 |  BioCentury  |  Emerging Company Profile

Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies. Antibodies can act on their targets with better...
18:52 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest vaccination during pregnancy with a vaccine based on RSV F and G proteins could help prevent RSV infection in offspring. The vaccine consists of Newcastle disease virus-like...
23:44 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Bavarian Nordic reports Phase II data for MVA-BN RSV for respiratory syncytial virus

In September, Bavarian Nordic A/S (CSE:BAVA) reported data from a Phase II trial in 421 healthy volunteers aged ≥55 showing that MVA-BN RSV led to a persistent antibody response against undisclosed RSV targets at 6...
21:06 , Nov 16, 2017 |  BC Innovations  |  Emerging Company Profile

YAP off, YAP on

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers....
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
00:48 , Dec 20, 2016 |  BC Week In Review  |  Clinical News

MVA-BN RSV: Completed Ph II enrollment

Bavarian Nordic completed enrollment of about 400 healthy volunteers ages ≥55 in a single-blind, placebo-controlled, U.S. Phase II trial evaluating 2 dose levels of MVA-BN RSV given once or twice 4 weeks apart. Bavarian Nordic...
07:00 , Sep 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Biased against pain

In a departure from the rote tweaking of morphinan structures to find better and safer opioids, an academic collaboration has used a powerful, computer-based screen of more than 3 million molecules to identify a new...
08:00 , Jan 14, 2016 |  BC Innovations  |  Tools & Techniques

"And" not "or" in psoriasis

Diseases with dynamic, irregular flare-ups like psoriasis may now have a therapeutic platform that can automatically keep up. A Swiss group has designed implantable cells that can detect and treat psoriatic inflammation using cytokine-based Boolean...
07:00 , Jul 27, 2015 |  BioCentury  |  Emerging Company Profile

Confo(rmation) active

Drug discovery against GPCRs can be difficult because the proteins quickly fall apart when removed from their natural membrane environment. Confo Therapeutics N.V. has developed Confobodies, which mimic the role of the G protein to...